Anavex Life Sciences (AVXL) Competitors $9.09 -0.28 (-2.99%) Closing price 04:00 PM EasternExtended Trading$9.08 -0.01 (-0.11%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL vs. KYMR, TLX, AMRX, NAMS, RARE, SRRK, XENE, VKTX, MOR, and IMVTShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Kymera Therapeutics (KYMR), Telix Pharmaceuticals (TLX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), MorphoSys (MOR), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. Its Competitors Kymera Therapeutics Telix Pharmaceuticals Amneal Pharmaceuticals NewAmsterdam Pharma Ultragenyx Pharmaceutical Scholar Rock Xenon Pharmaceuticals Viking Therapeutics MorphoSys Immunovant Kymera Therapeutics (NASDAQ:KYMR) and Anavex Life Sciences (NASDAQ:AVXL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Do insiders and institutionals hold more shares of KYMR or AVXL? 31.6% of Anavex Life Sciences shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, KYMR or AVXL? Anavex Life Sciences has lower revenue, but higher earnings than Kymera Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M71.82-$223.86M-$3.47-13.63Anavex Life SciencesN/AN/A-$43M-$0.57-15.95 Is KYMR or AVXL more profitable? Anavex Life Sciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Anavex Life Sciences N/A -45.67%-40.21% Which has more risk & volatility, KYMR or AVXL? Kymera Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Does the media favor KYMR or AVXL? In the previous week, Anavex Life Sciences had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 17 mentions for Anavex Life Sciences and 5 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.29 beat Anavex Life Sciences' score of 0.40 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 2 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer KYMR or AVXL? Kymera Therapeutics presently has a consensus target price of $58.76, suggesting a potential upside of 24.29%. Anavex Life Sciences has a consensus target price of $44.00, suggesting a potential upside of 384.05%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 3.06Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKymera Therapeutics beats Anavex Life Sciences on 10 of the 16 factors compared between the two stocks. Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$804.83M$3.15B$5.78B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-15.9521.2474.8626.40Price / SalesN/A456.43540.53124.73Price / CashN/A44.4425.8129.91Price / Book6.409.6413.256.28Net Income-$43M-$53.20M$3.29B$270.38M7 Day Performance-2.78%0.44%0.47%2.70%1 Month Performance-8.55%4.26%4.60%5.99%1 Year Performance71.19%9.43%73.42%25.94% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.6414 of 5 stars$9.09-3.0%$44.00+384.0%+76.5%$804.83MN/A-15.9540Positive NewsGap UpKYMRKymera Therapeutics2.4715 of 5 stars$43.26-0.6%$58.76+35.8%+2.0%$3.09B$47.07M-12.47170Positive NewsTLXTelix Pharmaceuticals3.6552 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.06B$637.77M0.00N/AHigh Trading VolumeAMRXAmneal Pharmaceuticals3.3443 of 5 stars$9.73+1.1%$11.60+19.2%+16.0%$3.06B$2.79B973.978,100Positive NewsNAMSNewAmsterdam Pharma3.3528 of 5 stars$25.09-7.1%$41.55+65.6%+51.6%$3.04B$64.01M-15.494Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3796 of 5 stars$31.51-1.0%$81.50+158.6%-48.4%$3.04B$560.23M-5.701,294Positive NewsSRRKScholar Rock4.4705 of 5 stars$31.58+0.5%$45.75+44.9%+269.5%$3.04B$33.19M-10.85140Positive NewsAnalyst ForecastGap UpXENEXenon Pharmaceuticals2.3889 of 5 stars$38.19-2.6%$53.30+39.6%-11.3%$2.94B$9.43M-10.76210Positive NewsVKTXViking Therapeutics4.1753 of 5 stars$25.48-5.6%$86.92+241.1%-62.8%$2.86BN/A-16.6520Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant2.4635 of 5 stars$16.37-4.5%$33.60+105.3%-45.5%$2.85BN/A-5.74120Positive News Related Companies and Tools Related Companies KYMR Alternatives TLX Alternatives AMRX Alternatives NAMS Alternatives RARE Alternatives SRRK Alternatives XENE Alternatives VKTX Alternatives MOR Alternatives IMVT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVXL) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVXL Stock Alerts